Clinical Trials Logo

Autoimmune Pancreatitis clinical trials

View clinical trials related to Autoimmune Pancreatitis.

Filter by:

NCT ID: NCT03241797 Completed - Clinical trials for Autoimmune Pancreatitis

Evaluation of EUS-guided FNA for Diagnosing Autoimmune Pancreatitis

Start date: January 2013
Phase: N/A
Study type: Interventional

The aim is to evaluate EUS-FNA efficacy for AIP diagnosis using a 22-gauge (G) needle.

NCT ID: NCT02797665 Recruiting - Clinical trials for Obstructive Jaundice

Treatment of Obstructive Jaundice in Autoimmune Pancreatitis and/or Immunoglobulin G4-related Sclerosing Cholangitis by Corticosteroids

Start date: May 2016
Phase: N/A
Study type: Interventional

This study evaluates corticosteroids in the treatment of obstructive jaundice in autoimmune pancreatitis and/or immunoglobulin G4 (IgG4)-related sclerosing cholangitis in adults. Half of participants will receive corticosteroids alone, while the other half will receive corticosteroids with biliary stent at the beginning.

NCT ID: NCT02766842 Withdrawn - Lymphoma Clinical Trials

Evaluation of a New EUS Guided Biopsy Needle (SharkCore) Comparing to Standard EUS Needle (ProCore)

Start date: April 2016
Phase: Phase 2
Study type: Interventional

Diagnosis of lesions of pancreas, the upper gastrointestinal tract, as well as adjacent structures, such as lymph nodes, is still showing advancements especially with the increased use of endoscopic ultrasound. Endoscopic ultrasound-guided fine needle aspiration and fine needle biopsy (EUS-FNA/FNB) have become mainstay diagnostic techniques for these lesions. The purpose of the study is to compare between the currently used, ProCore needles and the new biopsy needle, SharkCore, for the histological diagnosis and evaluation of lesions.

NCT ID: NCT02705638 Completed - Clinical trials for IgG4-related Disease

Treatment of IgG4-Related Disease With Revlimid and Rituximab

TIGR2
Start date: April 2016
Phase: Phase 1
Study type: Interventional

Among persons with Immunoglobulin G subclass 4 Related Disease (IgG4)-related disease who have persistent or recurrent disease despite standard therapies, does combination therapy with rituximab and revlimid cause a sustained disease remission?

NCT ID: NCT01845467 Withdrawn - Clinical trials for Autoimmune Pancreatitis

Efficacy of Secretin MRCP in the Diagnosis and Follow up of Auto Immune Pancreatitis

S-MRCP
Start date: February 2013
Phase:
Study type: Observational

BACKGROUND: Auto immune pancreatitis (AIP), a benign pancreatic disease has certain morphological forms which mimics pancreatic malignancy in radiological appearance. There is no singe diagnostic test which can accurately differentiate these two conditions. In the past, AIP accounted for up to 27% of Whipple resections performed for suspected adenocarcinoma. AIMS: To evaluate the efficacy of Secretin assisted Magnetic resonance cholangio pancreatography (MRCP) in differentiating AIP and pancreatic malignancy. METHODS: 100 patients suspected with AIP will be consented to participate in the study to undergo secretin MRCP in addition to their other standard investigations. Patients will be categorized as those with AIP and with pancreatic malignancy based on these results and will be followed. Follow up will eventually give the true diagnosis when patients with pancreatic malignancy undergo pancreatic surgery and their pancreatic tissue is examined by histopathologist. AIP patients will undergo steroid trial which will give the true diagnosis. The preliminary diagnosis results based on standard investigations with and without inclusion of secretin MRCP will be compared to the true diagnosis.

NCT ID: NCT01774513 Recruiting - Clinical trials for Autoimmune Pancreatitis

EUS-guided Procore-biopsy in Diagnosing Autoimmune Pancreatitis

Start date: January 2013
Phase: N/A
Study type: Interventional

The goal of this prospective study is to evaluate the feasibility of the Core Biopsy Needle with reverse bevel (Procore TM) in diagnosing autoimmune pancretitis

NCT ID: NCT01584388 Completed - Clinical trials for Autoimmune Pancreatitis

Rituximab in IgG4-related Disease: A Phase 1-2 Trial

Start date: April 2012
Phase: Phase 1/Phase 2
Study type: Interventional

The primary objective of this study is to evaluate the safety and effectiveness of rituximab in IgG4-RD.

NCT ID: NCT00588367 Completed - Clinical trials for Pancreatic Ductal Adenocarcinoma

CT Pancreas Perfusion

Start date: April 2006
Phase: N/A
Study type: Observational

1. Pancreatic CT perfusion with a biofeedback breathing belt worn by the participant, and using novel post-processing techniques, is a reliable method which can be used to differentiate between pancreatic cancer, chronic pancreatitis, and autoimmune pancreatitis. 2. Pancreatic CT perfusion can be used to monitor patients undergoing decompression treatment (endoscopic retrograde cholangiopancreatography with stent placement) for painful chronic pancreatitis, and the change in the pancreatic perfusion parameters correlate with the change in the pain parameters (pain scale and analgesic use). 3. Pancreatic CT perfusion parameters can be calculated using surrogate scan data sets at specific time points to replace the continuous scanning.